Economic evaluation of the artificial liver support system MARS in patients with acute-on-chronic liver failure

被引：18

作者：

Hessel F.P. ^{[1
]}

机构：

[1] Institute for Health Care Management, University of Duisburg-Essen, Schützenbahn D-45127 Essen, Campus Essen

来源：

Cost Effectiveness and Resource Allocation | / 4卷 / 1期

关键词：

Hepatic Encephalopathy; Incremental Cost; Direct Medical Cost; ACLF Patient; Initial Hospital Stay;

D O I：

10.1186/1478-7547-4-16

中图分类号：

学科分类号：

摘要：

Background: Acute-on-chronic liver failure (ACLF) is a life threatening acute decompensation of a pre-existing chronic liver disease. The artificial liver support system MARS is a new emerging therapeutic option possible to be implemented in routine care of these patients. The medical efficacy of MARS has been demonstrated in first clinical studies, but economic aspects have so far not been investigated. Objective of this study was to estimate the cost-effectiveness of MARS. Methods: In a clinical cohort trial with a prospective follow-up of 3 years 33 ACLF-patients treated with MARS were compared to 46 controls. Survival, health-related quality of life as well as direct medical costs for in- and outpatient treatment from a health care system perspective were determined. Based on the differences in outcome and indirect costs the cost-effectiveness of MARS expressed as incremental costs per life year gained and incremental costs per QALY gained was estimated. Results: The average initial intervention costs for MARS were 14600 EUR per patient treated. Direct medical costs over 3 years follow up were overall 40000 EUR per patient treated with MARS respectively 12700 EUR in controls. The 3 year survival rate after MARS was 52% compared to 17% in controls. Kaplan-Meier analysis of cumulated survival probability showed a highly significant difference in favour of MARS. Incremental costs per life-year gained were 31400 EUR; incremental costs per QALY gained were 47200 EUR. Conclusion: The results after 3 years follow-up of the first economic evaluation study of MARS based on empirical patient data are presented. Although high initial treatment costs for MARS occur the significantly better survival seen in this study led to reasonable costs per live year gained. Further randomized controlled trials investigating the medical efficacy and the cost-effectiveness are recommended. © 2006 Hessel; licensee BioMed Central Ltd.

引用

共 24 条

[1]

Boker K.H., Acute liver failure, Internist (Berl), 42, 4, pp. 556-562, (2001)

[2]

Lee W.M., Acute liver failure in the United States, Semin Liver Dis, 23, 3, pp. 217-226, (2003)

[3]

Bauer M., Winning J., Kortgen A., Liver failure, Curr Opin Anaesthesiol, 18, 2, pp. 111-116, (2005)

[4]

Sen S., Williams R., Jalan R., Emerging indications for albumin dialysis, Am J Gastroenterol, 100, 2, pp. 468-475, (2005)

[5]

Stange J., Hassanein T.I., Mehta R., Mitzner S.R., Bartlett R.H., The molecular adsorbents recycling system as a liver support system based on albumin dialysis: A summary of preclinical investigations, prospective, randomized, controlled clinical trial, and clinical experience from 19 centers, Artif Organs, 26, 2, pp. 103-110, (2002)

[6]

Stange J., Mitzner S.R., Risler T., Erley C.M., Lauchart W., Goehl H., Klammt S., Peszynski P., Freytag J., Hickstein H., Lohr M., Liebe S., Schareck W., Hopt U.T., Schmidt R., Molecular adsorbent recycling system (MARS): Clinical results of a new membrane-based blood purification system for bioartificial liver support, Artif Organs, 23, 4, pp. 319-330, (1999)

[7]

Steiner C., Mitzner S., Experiences with MARS liver support therapy in liver failure: Analysis of 176 patients of the International MARS Registry, Liver, 22, SUPPL. 2, pp. 20-25, (2002)

[8]

Mitzner S., Klammt S., Stange J., Noldge-Schomburg G.F., Schmidt R., Extracorporeal blood purification in severe liver failure with the albumin dialysis MARS - Impact on relevant intensive care parameters, Anasthesiol Intensivmed Notfallmed Schmerzther, 40, 4, pp. 199-206, (2005)

[9]

Jalan R., Sen S., Steiner C., Kapoor D., Alisa A., Williams R., Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis, J Hepatol, 38, 1, pp. 24-31, (2003)

[10]

Hessel F.P., Reimbursement of high-prized new emerging Medical Devices in a DRG-based Hospital Care System - The German Situation, Expert Reviews in Pharmacoeconomics and Outcomes Research, 5, pp. 377-381, (2005)

← 1 2 3 →